Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
RNA vaccines are composed of the nucleic acid RNA, which encode antigen genes of an infectious agent. When administered to host cells, the RNA is translated into protein antigens that elicit protective immunity against the infectious agent.
Serum neutralizing antibody titers against the SARS-CoV-2 Omicron variant markedly increase following a third dose of BNT162b2 in individuals who had previously received either two doses of the BNT162b2 vaccine or two doses of the CoronaVac vaccine.
Peripheral ancestral SARS-CoV-2 spike-specific CD4+ and CD8+ T cells induced by BNT162b2 vaccination cross-react to the Omicron variant at higher levels than those induced by prior SARS-CoV-2 infection
Saegerman et al. perform saliva SARS-CoV-2 testing in a cohort of nursing home workers in Belgium who are either unvaccinated or have received one or two doses of the BNT162b2 mRNA vaccine. The authors show that vaccination protects against shedding of SARS-CoV-2 into saliva and observe greater variability in viral load in the unvaccinated group.
mRNA technology may be uniquely positioned to tackle a major hurdle for HIV vaccines: the elicitation of broadly cross-reactive neutralizing antibodies. A preclinical study takes the first step toward this goal.
Katalin Karikó describes the discovery that replacing uridine with pseudouridine renders RNA non-immunogenic. This paved the way for developing mRNA for protein replacement therapy and, surprisingly, also for mRNA-based vaccine development.
2020 has witnessed unprecedented situations due to coronavirus pandemic that affected all aspects of life. The whole globe lived months of uncertainty before two companies have announced the incredible results of phase III clinical trials for two different mRNA-based vaccines.